Komori
Astellas Pharma (4503) · InitiativeAchieved

Discontinuation of Evrenzo development for chemotherapy-induced anemia

First written in FY2023. 1 of 1 entries say "Achieved", first in FY2023. Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of Evrenzo development for chemotherapy-associated anemiaA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023AchievedAnnual report

    「2022年10月　化学療法に伴う貧血を対象として臨床第Ⅱ相段階にあった開発を当社の権利範囲において中止したことを公表しました。」

    エベレンゾについて、化学療法に伴う貧血を対象とする第Ⅱ相開発を中止した。別途、将来計画の見直しに伴う47,077百万円の減損損失も認識した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.